MediPharm Labs Corp.
LABS.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 42.70% | -16.43% | 23.89% | 33.14% | 36.37% |
| Total Depreciation and Amortization | -17.79% | -27.59% | -37.51% | -35.64% | -34.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 64.86% | -12.05% | -31.59% | -95.50% | -46.07% |
| Change in Net Operating Assets | 203.22% | 228.73% | -94.57% | -120.28% | -129.18% |
| Cash from Operations | 86.90% | 46.98% | -9.84% | -191.46% | -47.24% |
| Capital Expenditure | 61.23% | 66.06% | 36.40% | 38.94% | 65.87% |
| Sale of Property, Plant, and Equipment | -88.76% | 22,207.19% | 712.04% | 519.31% | 55.75% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -89.83% | 3,150.14% | 984.30% | -5.58% | -37.90% |
| Total Debt Issued | -16.91% | -37.42% | -37.42% | -37.42% | -26.57% |
| Total Debt Repaid | 80.49% | 79.95% | 77.32% | 74.04% | -147.96% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -8.06% | -32.79% | -55.50% | -53.90% | -64.97% |
| Cash from Financing | 101.66% | 102.73% | 99.50% | 96.32% | -3,250.97% |
| Foreign Exchange rate Adjustments | -62.64% | 201.67% | 234.21% | 100.18% | 106.52% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 90.84% | 116.99% | 87.92% | -1,709.47% | -546.65% |